NASHVILLE, Tenn. and TORONTO, Ontario—Harrow, Inc. (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, and Apotex Inc., Canada’s largest pharmaceutical company, jointly announced an exclusive out-licensing agreement under which Apotex will market and distribute Verkazia and over-the-counter (OTC) Cationorm Plus in the Canadian market, and, concurrently, pursue market approval in Canada for Vevye, Iheezo and Zerviate. “We are pleased to enter the Canadian market through this partnership with Apotex, which has a proven track record of success serving Canadian eyecare professionals and their patients,” said Mark L. Baum, chairman and CEO of Harrow.

“This exclusive agreement fulfills our commitment to access and availability of these five important ophthalmic pharmaceutical products, and we look forward to working closely with our partners at Apotex over the coming years as they seek approval for Vevye, Iheezo and Zerviate in the Canadian market,” Baum said.

“We are excited to partner with Harrow to provide access to an innovative branded line of ophthalmic products that complement our existing portfolio,” stated Allan Oberman, president and chief executive officer of Apotex. “This alliance expands Apotex’s product offering in Canada to include innovative patented pharmaceutical medicines, aligned with our ongoing strategic focus to further expand our innovative branded pharmaceutical therapeutic areas of focus in becoming a Canadian-based global health company.”

“Adding these products strengthens our therapeutic line and provides Canadian patients with valuable new treatment options,” added Mike Woolcock, senior vice president, Biosimilars & Specialty. “We look forward to collaborating with Harrow to expand this line with Vevye, Iheezo and Zerviate upon receiving market approval to improve the overall patient quality of life in this category.”